Dyadic International, Inc. (NASDAQ:DYAI) is set to announce second quarter earning results on Thursday 13th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, DYAI to report 2Q20 loss of $ 0.04 per share from revenue of $ 1.33 million.
For the full year, analysts anticipate top line of $ 4.25 million, while looking forward to loss of $ 0.23 per share bottom line.
Previous Quarter Performance
Dyadic International, Inc. unveiled loss for the first quarter of $ 0.08 per share, from the revenue of $ 0.32 million. The quarterly revenues down 20.00 percent compared with the same quarter last year. Wall street analysts are predicting, DYAI to report 1Q20 loss of $ 0.02 per share from revenue of $ 2.07 million. The bottom line results missed street analysts by $ 0.06 or 300 percent, at the same time, top line results fell short of analysts by $ 1.75 million or 84.54 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Dyadic International, Inc.
Stock Performance
According to the previous trading day, closing price of DYAI was $ 8.76, representing a 249.00 % increase from the 52 week low of $ 2.51 and a 20.22 % decrease over the 52 week high of $ 10.98.
The company has a market capital of $ 240.54 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”DYAI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc.
